Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Adaptimmune, Genentech Enter Strategic R&D Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Adaptimmune, Genentech Enter Strategic R&D Collaboration

To research, develop, and commercialize cancer-targeted Allogeneic T-cell therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Adaptimmune Therapeutics plc has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group, to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.
 
The collaboration entails the development of allogeneic T-cell therapies for up to five shared cancer targets, and development of personalized allogeneic T-cell therapies.
 
Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells). Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization.
 
Adaptimmune will receive $150 million upfront and additional payments of $150 million over five years, unless the agreement is terminated earlier. Adaptimmune may also be eligible to receive research, development, regulatory and commercial milestones potentially exceeding $3 billion in total, and royalties on sales.
 
Adaptimmune has the right to opt in to a 50/50 U.S. profit/cost share on “off-the-shelf” products. If Adaptimmune elects to opt in, then Adaptimmune will be eligible to share 50 percent of profits and losses from U.S. sales on such products and is eligible to receive ex-U.S. regulatory and sales-based milestone payments, as well as royalties on ex-U.S. net sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics